Glenmark appoints Dr. Kurt Stoeckli as President and Chief Scientific Officer

Dr. Stoeckli will oversee Glenmark’s entire research portfolio including biologics (NBEs) and small molecules (NCEs)

aaeaaqaaaaaaaaaiaaaajdq5zwrmnzg3lwzlzditndu3zi04mjlhlwziyjq4mjvimmuwyq

Dr. Kurt Stoeckli (Photo: LinkedIn/Kurt Stoeckli)

Glenmark has announced the appointment of Dr. Kurt Stoeckli as President and Chief Scientific Officer (CSO). Dr. Stoeckli joins Glenmark from SANOFI where he was Group Vice President, Global Biopharmaceuticals Division & Chief Scientific Officer for R&D France.

He will report to Glenn Saldanha, Chairman and MD and will be based out of Neuchâtel, Switzerland. He will also be President and General Manager of Glenmark's Switzerland-based business units.

Dr. Stoeckli will lead the company's global research portfolio consisting of NBE, NCE, generics and branded formulations. He will be responsible for sustaining and enhancing the environment of collaborative research and for driving successful commercialization of Glenmark' research pipeline in partnership with other leaders.

"We are pleased to bring Dr. Stoeckli's expertise to Glenmark which will further drive the advancement of our new molecular entity portfolio and enable us to continue discovering NMEs both small molecules and biologics," said Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals Ltd. "Dr. Stoeckli's invaluable scientific knowledge and leadership will enable us to achieve our goal of becoming a global innovative pharmaceutical organisation."

Having spent more than two decades in the pharmaceutical industry, Dr. Stoeckli has an extensive industry experience in driving biologics from early research up to phase 3. He has played a pivotal role in fostering and managing Sanofi's JV with Regeneron Pharmaceuticals Inc.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X